Medicare to cover weight-loss drugs through a temporary program
The Trump administration will offer GLP-1 weight-loss drugs to Medicare beneficiaries aged 65 and older for the first time, working around a law that bars Medicare from paying for obesity drugs . Because a permanent fix would require Congress, the administration is using a temporary demonstration program called Bridge; coverage is set to begin in July and run through the end of 2027.
The route reflects how the plan came together. The government had first sought a three-year voluntary arrangement with private insurers, called BALANCE, but insurers balked, so officials fell back on the time-limited Bridge demonstration instead.
The headline concern is structural: once seniors gain subsidized access to popular and expensive drugs, withdrawing the benefit becomes politically costly, which is how a “temporary” program tends to harden into a standing entitlement without a clear funding source. The fiscal stakes are large given GLP-1 list prices and the share of Medicare enrollees who would qualify on weight alone.